# US 2024/0142466 A1 · Urinary tract infection diagnostic

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0142466 A1
- Document ID: US20240142466A1
- Status: Published application
- Kind: A1
- Application number: 18/407,865
- Filed: 2024-01-09
- Published: 2024-05-02
- Earliest claimed: 2017-03-01
- Assignees: Mologic Limited
- Applicants: Mologic Limited
- Inventors: Gita Parekh; Paul Davis; Julie Thompson; Annelyse Duvoix
- Web page: https://patentgrep.com/patent/US20240142466A1

## CPC

- G01N 33/56911: {Bacteria}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 33/54366: {Apparatus specially adapted for solid-phase testing}
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G01N 2333/5412: IL-6
- G01N 2333/5421: IL-8
- G01N 2333/545: IL-1
- G01N 2333/75: Fibrin; Fibrinogen
- G01N 2333/765: Serum albumin, e.g. HSA
- G01N 2333/908: acting on hydrogen peroxide as acceptor (1.11)
- G01N 2333/96486: Metalloendopeptidases (3.4.24)
- G01N 2333/96494: Matrix metalloproteases, e. g. 3.4.24.7
- G01N 2333/966: Elastase
- G01N 2800/348: Urinary tract infections
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Method for detecting a urinary tract infection (UTI) in a subject comprising determining levels of one or more biomarkers selected from MMP8, HNE, Cystatin C, MMP9, HSA, IL-8, interleukin-6 (IL-6), interleukin-1 beta (IL-1b), fibrinogen, RBP4, active MMP9 and MMP2, NGAL, Desmosine, MPO and CRP in a urine sample obtained from the subject. The determined levels may then be compared with a threshold level, wherein increased levels of at least one of the biomarkers in the urine sample relative to the threshold level is indicative of the presence of a urinary tract infection. Methods for monitoring a UTI and monitoring treatment of a UTI are also provided as are companion systems or test kits.

## Claims

### Claim 1

A method for detecting a urinary tract infection in a subject comprising:
i) determining levels of one or more biomarkers selected from MMP8, HNE, Cystatin C, MMP9, HSA, IL-8, interleukin-6 (IL-6), interleukin-1 beta (IL-1b), fibrinogen, RBP4, active MMP9 and MMP2, NGAL, Desmosine, MPO and CRP in a urine sample obtained from the subject; and
ii) comparing each determined level with a threshold level wherein increased levels of at least one of the biomarkers in the urine sample relative to the threshold level is indicative of the presence of a urinary tract infection.

### Claim 2

A method for monitoring a urinary tract infection in a subject comprising:
i) determining levels of one or more biomarkers selected from MMP8, HNE, Cystatin C, MMP9, HSA, IL-8, interleukin-6 (IL-6), interleukin-1 beta (IL-1b), fibrinogen, RBP4, active MMP9 and MMP2, NGAL, Desmosine, MPO and CRP in urine samples obtained from the subject at multiple time points; and
ii) comparing each determined level with a threshold level
wherein the continued presence of non-decreased or increased levels of at least one of the biomarkers relative to the threshold level or relative to the levels measured in a sample taken from an earlier time point is indicative that the urinary tract infection persists and/or that treatment has not been effective and/or decreased levels of at least one of the biomarkers relative to the threshold level or relative to the levels measured in a sample taken from an earlier time point is indicative of recovery from, or successful treatment of, a urinary tract infection.

### Claim 3 (depends on 1)

A method for detecting and monitoring a urinary tract infection in a subject comprising:
i) performing the method of claim 1; and, where a urinary tract infection is detected
ii) determining levels of one or more biomarkers selected from MMP8, HNE, Cystatin C, MMP9, HSA, IL-8, interleukin-6 (IL-6), interleukin-1 beta (IL-1b), fibrinogen, RBP4, active MMP9 and MMP2, NGAL, Desmosine, MPO and CRP in a further urine sample obtained from the subject at a later time point
wherein non-decreased or increased levels of at least one of the biomarkers relative to the threshold level or to the levels measured in step (i) is indicative that the urinary tract infection persists and/or decreased levels of at least one of the biomarkers relative to the threshold level or to the levels measured in step (i) is indicative of recovery from, or successful treatment of, the urinary tract infection.

### Claim 4

A method for monitoring treatment of a urinary tract infection in a subject comprising:
i) determining levels of one or more biomarkers selected from MMP8, HNE, Cystatin C, MMP9, HSA, IL-8, interleukin-6 (IL-6), interleukin-1 beta (IL-1b), fibrinogen, RBP4, active MMP9 and MMP2, NGAL, Desmosine, MPO and CRP in a urine sample obtained from the subject prior to treatment of the urinary tract infection in order to set a threshold level;
ii) determining levels of one or more biomarkers selected from MMP8, HNE, Cystatin C, MMP9, HSA, IL-8, interleukin-6 (IL-6), interleukin-1 beta (IL-1b), fibrinogen, RBP4, active MMP9 and MMP2, NGAL, Desmosine, MPO and CRP in a further urine sample obtained from the subject following treatment of the urinary tract infection
wherein non-decreased or increased levels of at least one of the biomarkers relative to the threshold level is indicative that the treatment has not been effective and/or decreased levels of at least one of the biomarkers relative to the threshold level is indicative of successful treatment of the urinary tract infection.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4 wherein the levels of at least two or three of the biomarkers are determined.

### Claim 6 (depends on 5)

The method of claim 5 wherein non-decreased or increased levels of at least two or three, optionally all, of the biomarkers in the urine sample relative to the threshold level or relative to the levels measured in a sample taken from an earlier time point are indicative of the presence of a urinary tract infection.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6 comprising determining the levels of:
a. at least one of MMP8 or HNE, optionally both MMP8 and HNE;
b. at least one of MMP8, HNE, fibrinogen or CRP, optionally:
(i) MMP8, HNE and fibrinogen; or
(ii) MMP8, HNE and CRP; or
c. at least one of NGAL, MMP9, Desmosine or MPO, optionally all of (i) NGAL, MMP9 and Desmosine or (ii) NGAL, MMP9, Desmosine and MPO.

### Claim 8 (depends on 7)

The method of claim 7 further comprising determining the levels of Cystatin C.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8 wherein the biomarkers are:
(i) MMP8, HNE and Cystatin C; or
(ii) MMP8, HNE and fibrinogen; or
(iii) MMP8, HNE and CRP.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9 wherein at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 or more samples are taken from the subject at different times and the levels of the one or more biomarkers is determined.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10 wherein the samples are taken every 6 to 24 hours, such as daily, or every 3, 4, 5, 6, 7 or 14 days.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of selecting a subject for treatment with an antibiotic comprising performing the method of any one of claims 1-11 and selecting the subject for treatment where a urinary tract infection is detected or persists.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of predicting responsiveness of a subject to treatment with an antibiotic comprising performing the method of any one of claims 1-11 and predicting responsiveness of the subject to treatment where a urinary tract infection is detected or persists.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treating a urinary tract infection comprising administering an antibiotic to the subject suffering from a urinary tract infection, wherein the subject has been selected for treatment by performing the method of any one of claims 1-11.

### Claim 15

A method of treating a urinary tract infection comprising administering an antibiotic to the subject suffering from a urinary tract infection, wherein the subject displays, in a urine sample, an increased level of at least one biomarker selected from MMP8, HNE, Cystatin C, MMP9, HSA, IL-8, interleukin-6 (IL-6), interleukin-1 beta (IL-1b), fibrinogen, RBP4, active MMP9 and MMP2, NGAL, Desmosine, MPO and CRP.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

An antibiotic for use in a method of treating a urinary tract infection wherein the subject has been selected for treatment by performing the method of any one of claims 1-11.

### Claim 17

An antibiotic for use in a method of treating a urinary tract infection wherein the subject displays, in a urine sample, an increased level of at least one biomarker selected from MMP8, HNE, Cystatin C, MMP9, HSA, IL-8, interleukin-6 (IL-6), interleukin-1 beta (IL-1b), fibrinogen, RBP4, active MMP9 and MMP2, NGAL, Desmosine, MPO and CRP.

### Claim 18 (depends on 12, 13, 14, 15, 16, 17)

The method of any one of claims 12-15 or antibiotic for use of claim 16 or 17, wherein the antibiotic is selected from aminoglycoside, a cephalosporin, a glycopeptide, a penicillin, a quinolone, aztreonam, clindamycin, imipenem-cilastin, linezolid, metronidazole, rifampin, an antifungal and an antiviral.

### Claim 19

A system or test kit for detecting a urinary tract infection in a subject, comprising:
a. One or more testing devices for determining levels of one, two, three or more biomarkers selected from MMP8, HNE, Cystatin C, MMP9, HSA, IL-8, interleukin-6 (IL-6), interleukin-1 beta (IL-1b), fibrinogen, RBP4, active MMP9 and MMP2, NGAL, Desmosine, MPO and CRP in a urine sample obtained from the subject
b. A processor; and
c. A storage medium comprising a computer application that, when executed by the processor, is configured to:
i. Access and/or calculate the determined levels of each biomarker in the sample on the one or more testing devices
ii. Calculate a test score from the levels of the biomarkers in the sample that detects a urinary tract infection; and
iii. Output from the processor the detected result for the subject.

### Claim 20

A system or test kit for monitoring a urinary tract infection in a subject, comprising:
a. One or more testing devices for determining levels of one, two, three or more biomarkers selected from MMP8, HNE, Cystatin C, MMP9, HSA, IL-8, interleukin-6 (IL-6), interleukin-1 beta (IL-1b), fibrinogen, RBP4, active MMP9 and MMP2, NGAL, Desmosine, MPO and CRP in a urine sample obtained from the subject at multiple time points
b. A processor; and
c. A storage medium comprising a computer application that, when executed by the processor, is configured to:
i. Access and/or calculate the determined levels of each biomarker in the sample on the one or more testing devices
ii. Calculate a test score from the levels of the biomarkers in the sample, optionally including a comparison of the levels with those taken at one or more earlier time points, that detects a urinary tract infection; and
iii. Output from the processor the detected result for the subject.

### Claim 21 (depends on 19, 20)

The system or test kit of any one of claim 19 or 20 wherein the biomarkers comprise:
a. at least one of MMP8, HNE, fibrinogen or CRP, optionally both MMP8 and HNE;
b. at least one of MMP8, HNE, fibrinogen or CRP, optionally:
(i) MMP8, HNE and fibrinogen; or
(ii) MMP8, HNE and CRP; or
c. at least one of NGAL, MMP9 or Desmosine, optionally all of (i) NGAL, MMP9 and Desmosine or (ii) NGAL, MMP9, Desmosine and MPO.

### Claim 22 (depends on 21)

The system or test kit of claim 21 wherein the biomarkers further comprise Cystatin C.

### Claim 23 (depends on 19, 20, 21, 22)

The system or test kit of any one of claims 19-22 wherein the biomarkers are:
(i) MMP8, HNE and Cystatin C; or
(ii) MMP8, HNE and fibrinogen; or
(iii) MMP8, HNE and CRP.

### Claim 24

A testing device, testing kit or testing composition of matter comprising:
a. A sample receiving zone to which a urine sample from a subject is added
b. A conjugate zone comprising at least one, two or three labelled binding reagents, each of which specifically binds to one of the biomarkers selected from MMP8, HNE, Cystatin C, MMP9, HSA, IL-8, interleukin-6 (IL-6), interleukin-1 beta (IL-1b), fibrinogen, RBP4, active MMP9 and MMP2, NGAL, Desmosine, MPO and CRP
c. A solid support defining a liquid flow path for the sample and comprising corresponding test lines for each of the at least one, two or three biomarkers, each test line comprising:
i. an immobilised further binding reagent that also specifically binds to one of the at least one, two or three biomarkers thereby immobilising the biomarker at the test line to produce a signal via the labelled binding reagent also specifically bound to the biomarker; or
ii. an immobilised version of one of the at least one, two or three biomarkers or an analogue thereof able to compete with the biomarker in the sample for specific binding to the labelled binding reagent.

### Claim 25 (depends on 24)

The testing device, testing kit or testing composition of matter of claim 24 further comprising:
d. At least one labelled control binding reagent that binds to a binding partner immobilised at a control line downstream of the test lines for the at least one, two or three biomarkers and thus confirms that the test has completed successfully.

### Claim 26 (depends on 24, 25)

The testing device, testing kit or testing composition of matter of claim 24 or 25 further comprising:
e. An absorbent material downstream of the test (and control, where present) lines to absorb excess sample.

### Claim 27 (depends on 24, 25, 26)

The testing device, testing kit or testing composition of matter of any one of claims 24-26 wherein the solid support comprises a chromatographic medium.

### Claim 28 (depends on 24, 25, 26, 27)

The testing device, testing kit or testing composition of matter of any one of claims 24-27 wherein the solid support comprises a capillary flow device.

### Claim 29 (depends on 24, 25, 26, 27, 28)

The testing device, testing kit or testing composition of matter of any one of claims 24-28 which is a test strip.

### Claim 30 (depends on 24, 25, 26, 27, 28, 29, 30)

The testing device, testing kit or testing composition of matter of any one of claims 24-29 further comprising a vessel for collecting a urine sample. 31 The testing device, testing kit or testing composition of matter of any one of claims 24-30 further comprising a visual aid displaying different test line intensity patterns from which the user can interpret the observed test line results.

### Claim 32 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32)

The testing device, testing kit or testing composition of matter of any one of claims 24-31 further comprising a reader to determine levels of the markers at the respective test lines. 33 The testing device, testing kit or testing composition of matter of claim 32 wherein the reader comprises:
a. A processor; and
b. A storage medium comprising a computer application that, when executed by the processor, is configured to:
i. Access and/or calculate the determined levels of each biomarker in the sample ii. Calculate a test score from the levels of the biomarkers in the sample that detects a urinary tract infection; and
iii. Output from the processor the detected result for the subject;
or
i. Access and/or calculate the determined levels of each biomarker in the sample on the one or more testing devices
ii. Calculate a test score from the levels of the biomarkers in the sample by comparing the levels with those taken at one or more earlier time points to thereby detect and/or monitor a urinary tract infection; and
iii. Output from the processor the detected result for the subject.

### Claim 34 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The testing device, testing kit or testing composition of matter of any one of claims 24-33 wherein the biomarkers comprise:
a. at least one of MMP8 or HNE, optionally both MMP8 and HNE;
b. at least one of MMP8, HNE, fibrinogen or CRP, optionally:
(i) MMP8, HNE and fibrinogen;
(ii) MMP8, HNE and CRP; or
c. at least one of NGAL, MMP9 or Desmosine, optionally all of (i) NGAL, MMP9 and Desmosine or (ii) NGAL, MMP9, Desmosine and MPO.

### Claim 35 (depends on 34)

The testing device, testing kit or testing composition of matter of claim 34(a) or 34(b) wherein the test line for each biomarker respectively comprises an immobilised further binding reagent that also specifically binds to each biomarker respectively thereby immobilising each biomarker at the respective test line to produce a signal via the labelled binding reagent also specifically bound to each biomarker.

### Claim 36 (depends on 34, 35)

The testing device, testing kit or testing composition of matter of claim 34 or 35 wherein the biomarkers further comprise Cystatin C.

### Claim 37 (depends on 36)

The testing device, testing kit or testing composition of matter of claim 36 wherein the test line for Cystatin C comprises an immobilised version of Cystatin C or an analogue thereof able to compete with Cystatin C in the sample for specific binding to the labelled binding reagent.

### Claim 38 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The testing device, testing kit or testing composition of matter of any one of claims 24-37 wherein the biomarkers are:
(i) MMP8, HNE and Cystatin C; or
(ii) MMP8, HNE and fibrinogen; or
(iii) MMP8, HNE and CRP.

### Claim 39 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The system or test kit of any one of claims 19-23 wherein the testing device is a testing device as claimed in any one of claims 24-38.
